Humanized anti-HER2 monoclonal antibody that blocks HER2 dimerization, particularly HER2–HER3.
Humanized anti-HER2 monoclonal antibody that binds the HER2 extracellular dimerization domain (subdomain II), preventing HER2 heterodimerization—especially HER2–HER3—thereby blocking downstream signaling (PI3K/AKT/MAPK), inhibiting tumor cell proliferation and survival; also mediates ADCC.
YES
DIRECT
Pertuzumab binds HER2 on target cells and its Fc engages Fcγ receptors on effector cells to trigger ADCC, leading to lysis of HER2+ cells; it also blocks HER2 dimerization/signaling, promoting apoptosis.
Off-the-shelf allogeneic CAR NK cell therapy with a logic-gated NOT design targeting CD33 and/or FLT3 and an inhibitory CAR to spare healthy cells; includes IL-15 support to enhance NK persistence/function for AML/MDS.
Off-the-shelf allogeneic NK cells engineered with an OR-gated activating CAR targeting CD33 and/or FLT3 and a NOT-gated inhibitory CAR recognizing EMCN to spare healthy hematopoietic stem cells; includes calibrated-release IL-15 to enhance NK persistence and function. Antigen engagement triggers NK activation and cytolytic killing of CD33/FLT3-positive AML/MDS cells while minimizing on-target/off-tumor toxicity.
YES
DIRECT
CAR-engineered NK cells recognize CD33 via the activating CAR and directly lyse target cells through NK degranulation (perforin/granzymes); an EMCN iCAR inhibits killing of EMCN+ healthy cells.
Off-the-shelf allogeneic CAR NK cell therapy with a logic-gated NOT design targeting CD33 and/or FLT3 and an inhibitory CAR to spare healthy cells; includes IL-15 support to enhance NK persistence/function for AML/MDS.
Off-the-shelf allogeneic NK cells engineered with an OR-gated activating CAR targeting CD33 and/or FLT3 and a NOT-gated inhibitory CAR recognizing EMCN to spare healthy hematopoietic stem cells; includes calibrated-release IL-15 to enhance NK persistence and function. Antigen engagement triggers NK activation and cytolytic killing of CD33/FLT3-positive AML/MDS cells while minimizing on-target/off-tumor toxicity.
YES
DIRECT
CAR NK cells bind FLT3 via the activating CAR, triggering NK activation and degranulation (perforin/granzymes) to lyse/apoptose FLT3+ cells; an inhibitory CAR for EMCN spares healthy HSCs.
Off-the-shelf allogeneic CAR NK cell therapy with a logic-gated NOT design targeting CD33 and/or FLT3 and an inhibitory CAR to spare healthy cells; includes IL-15 support to enhance NK persistence/function for AML/MDS.
Off-the-shelf allogeneic NK cells engineered with an OR-gated activating CAR targeting CD33 and/or FLT3 and a NOT-gated inhibitory CAR recognizing EMCN to spare healthy hematopoietic stem cells; includes calibrated-release IL-15 to enhance NK persistence and function. Antigen engagement triggers NK activation and cytolytic killing of CD33/FLT3-positive AML/MDS cells while minimizing on-target/off-tumor toxicity.
NO
INDIRECT
Endomucin is bound by an inhibitory CAR (NOT gate) on the engineered NK cells, delivering inhibitory signals that prevent NK activation and cytolytic killing, thereby sparing EMCN-expressing cells.
Off-the-shelf allogeneic CAR NK cell therapy with a logic-gated NOT design targeting CD33 and/or FLT3 and an inhibitory CAR to spare healthy cells; includes IL-15 support to enhance NK persistence/function for AML/MDS.
Off-the-shelf allogeneic NK cells engineered with an OR-gated activating CAR targeting CD33 and/or FLT3 and a NOT-gated inhibitory CAR recognizing EMCN to spare healthy hematopoietic stem cells; includes calibrated-release IL-15 to enhance NK persistence and function. Antigen engagement triggers NK activation and cytolytic killing of CD33/FLT3-positive AML/MDS cells while minimizing on-target/off-tumor toxicity.
NO
INDIRECT
SENTI-202 does not target IL-15Rα for killing; its secreted IL-15 engages IL-15Rα to stimulate immune cell survival/function. Cytotoxicity is directed only at CD33/FLT3+ cells via CAR NK degranulation (perforin/granzymes).